NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading ADMA? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on revenue growth and profitability. The current thesis state is intact, driven by recent strong financial performance, although revenue growth remains a concern.
The market currently prices ADMA as cheap compared to its peers, reflecting a significant expectations gap. This suggests that investors are not fully accounting for the company's recent improvements in profitability and cash flow.
Management is making progress in increasing profitability and enhancing cash flow from operations. However, revenue growth has been stagnant, which poses a risk to future performance.
The thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX. Positive earnings from these companies could provide a favorable backdrop, while any negative guidance could impact ADMA's momentum.
Over the next 1 to 3 years, ADMA's performance will depend on its ability to drive revenue growth and the overall health of the healthcare sector. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings report missed expectations. This miss raises concerns about the company's performance.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Earnings results will show revenue growth and profit trends. This is key for ADMA.
Confirms one read:Earnings report shows total revenue above $530 million for FY 2026.
Confirms the other:Earnings report shows total revenue below $530 million for FY 2026.
Why it matters: Hitting this revenue mark would show recovery from stagnation. It supports management's growth plan.
Confirms:Total revenue for Q2 exceeds $130 million.
Disproves:Total revenue for Q2 falls below $120 million.
Why it matters: Strong cash flow helps ADMA invest in growth. It also helps manage operations.
Confirms:Cash from operations exceeds $50 million in Q2 2026.
Disproves:Cash from operations falls below $50 million in Q2 2026.
Why it matters: Stable ordering patterns may show steady demand and help predict revenue.
Confirms one read:ADMA sees steady orders from distributors in Q2 2026.
Confirms the other:ADMA sees changes in orders from distributors in Q2 2026.
Why it matters: ASCENIV revenue growth shows strong demand. This supports ADMA's growth plans.
Confirms:ASCENIV revenue growth remains above 20% year over year in Q2 2026.
Disproves:ASCENIV revenue growth falls below 20% year over year in Q2 2026.
Why it matters: Updates on SG-001 may show future revenue chances. They could also mean market growth.
Confirms:ADMA shares good news or data about SG-001 development.
Disproves:ADMA reports delays or bad news about SG-001 development.
Why it matters: BIVIGAM revenue growth would show recovery from recent drops. It would mean market stability.
Confirms:BIVIGAM revenue improves from the previous quarter in Q2 2026.
Disproves:BIVIGAM revenue continues to decline in Q2 2026.
